Liver cancer patients: do targeted drugs before transplant boost survival?
NCT ID NCT07418138
First seen Feb 22, 2026 · Last updated May 08, 2026 · Updated 8 times
Summary
This study looked back at data from 484 liver cancer patients who had a liver transplant to see if taking targeted therapy (tyrosine kinase inhibitors) before the transplant helped them live longer or kept the cancer from coming back. The researchers checked survival rates, cancer recurrence, and liver function after surgery. The goal was to learn which factors affect patient outcomes after transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
First Affiliated Hospital Xian Jiaotong University
Xi'an, Shaanxi, 710061, China
Conditions
Explore the condition pages connected to this study.